Online inquiry

IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13127MR)

This product GTTS-WQ13127MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets APP gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ13127MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13686MR IVTScrip™ mRNA-Anti-TNFSF13B, RC18(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA RC18
GTTS-WQ296MR IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA 177lu-DOTA-HH1
GTTS-WQ14444MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA RO4858696-000
GTTS-WQ6305MR IVTScrip™ mRNA-Anti-TNFRSF10B, CS-1008(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CS-1008
GTTS-WQ12163MR IVTScrip™ mRNA-Anti-MSLN, MORAb-009(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MORAb-009
GTTS-WQ8634MR IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HuMax-AXL-ADC
GTTS-WQ885MR IVTScrip™ mRNA-Anti-PDCD1, ABBV-181(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-181
GTTS-WQ12393MR IVTScrip™ mRNA-Anti-SAA1, NEOD-001(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA NEOD-001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW